Resmed (RMD) Receives a Hold from Needham

In a report released today, Michael Matson from Needham maintained a Hold rating on Resmed (RMDResearch Report). The company’s shares closed last Thursday at $232.91.

According to, Matson is a 4-star analyst with an average return of 3.7% and a 48.2% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Resmed with a $202.49 average price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $301.34 and a one-year low of $189.40. Currently, Resmed has an average volume of 618.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Founded in 1989, California-based ResMed, Inc. is a medical equipment company. The company is engaged in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through two segments: Sleep and Respiratory Care, and SaaS (Software as a Service).

Read More on RMD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More